In this episode of PsyQ, the hosts discuss the 2023 article "The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns". They explain the physiological mechanisms of substances like psilocybin and MDMA, noting how they suppress the "Default Mode Network" to facilitate new neural pathways and promote neuroplasticity. While clinical trials show promise for treating major depression, end-of-life distress, and PTSD, the hosts emphasize a significant "demographic disconnect". Current research primarily involves young, healthy participants, yet older adults present complex medical realities, including polypharmacy and cardiovascular vulnerabilities. Specifically, the stimulation of 5-HT2A receptors can cause vasoconstriction and increase blood pressure, posing risks of stroke or arrhythmia in geriatric patients. The discussion concludes that while psychedelics offer a "breakthrough" potential for mental health, rigorous trials focused on the elderly are essential to determine if these high-dose therapies can be safely adapted for aging bodies.